Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V C Jordan

Showing results (301-310 of 365) with videos related to

Pageof 37
Sort By:
Cancer Research|October 4, 2000
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351J MacGregor Schafer, H Liu, D J Bentrem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic miceR C Dardes, D Bentrem, R M O'Regan, et al.
Molecular and Cellular Endocrinology|December 1, 1992
An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiolS Y Jiang, D M Wolf, J M Yingling, et al.
Breast Cancer Research and Treatment|February 1, 1990
Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2S P Robinson, D Goldstein, P L Witt, et al.
Molecular Endocrinology (Baltimore, Md.)|December 1, 1992
Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ERS Y Jiang, S M Langan-Fahey, A L Stella, et al.
Breast Cancer Research and Treatment|January 1, 1994
Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 ratsY P Dragan, S Fahey, K Street, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 1995
The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot)J N Sarkaria, J F Fowler, M J Lindstrom, et al.
Molecular and Cellular Endocrinology|August 1, 1993
Subcellular compartmentalization of MCF-7 estrogen receptor synthesis and degradationW V Welshons, L H Grady, B M Judy, et al.
Cancer Research|April 28, 2001
Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complexH Liu, E S Lee, A Deb Los Reyes, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 2001
Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cellsJ MacGregor Schafer, H Liu, A S Levenson, et al.
Pageof 37

Showing results (301-310 of 365) with videos related to

Sort By:
Pageof 37
Cancer Research|October 4, 2000
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351J MacGregor Schafer, H Liu, D J Bentrem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic miceR C Dardes, D Bentrem, R M O'Regan, et al.
Molecular and Cellular Endocrinology|December 1, 1992
An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiolS Y Jiang, D M Wolf, J M Yingling, et al.
Breast Cancer Research and Treatment|February 1, 1990
Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2S P Robinson, D Goldstein, P L Witt, et al.
Molecular Endocrinology (Baltimore, Md.)|December 1, 1992
Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ERS Y Jiang, S M Langan-Fahey, A L Stella, et al.
Breast Cancer Research and Treatment|January 1, 1994
Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 ratsY P Dragan, S Fahey, K Street, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 1995
The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot)J N Sarkaria, J F Fowler, M J Lindstrom, et al.
Molecular and Cellular Endocrinology|August 1, 1993
Subcellular compartmentalization of MCF-7 estrogen receptor synthesis and degradationW V Welshons, L H Grady, B M Judy, et al.
Cancer Research|April 28, 2001
Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complexH Liu, E S Lee, A Deb Los Reyes, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 2001
Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cellsJ MacGregor Schafer, H Liu, A S Levenson, et al.
Pageof 37